Escient – upcoming clinical trial for PBC itch
There is a new clinical trial aimed at PBC pruritus. While the study is currently in New Zealand and Australia, there are plans to expand the trial to PBC patients in North America. Escient Pharmaceuticals, Inc., an industry-leading company developing Mas-related G Protein-Coupled Receptor (MRGPR)-targeted drugs to address serious, underserved medical needs across a broad range of therapeutic indications, has initiated a Phase 1/1b clinical trial of EP547, a MRGPRX4-targeted product candidate to treat cholestatic and uremic pruritus. The Phase 1/1b trial of EP547 is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EP547 in healthy subjects and subjects with cholestatic or uremic pruritus. The study is being conducted in New Zealand and Australia and will inform the opportunity to conduct studies assessing safety and efficacy of EP547 in patients with cholestatic pruritus as a result of primary biliary cholangitis or primary sclerosing cholangitis.